ivacaftor
Selected indexed studies
- Elexacaftor/Ivacaftor/Tezacaftor: First Approval. (Drugs, 2019) [PMID:31784874]
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. (Lancet, 2019) [PMID:31679946]
- Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. (Am J Respir Crit Care Med, 2022) [PMID:34784492]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. (2022) pubmed
- Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation. (2025) pubmed
- Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy. (2024) pubmed
- Elexacaftor/Ivacaftor/Tezacaftor: First Approval. (2019) pubmed
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. (2019) pubmed
- VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. (2018) pubmed
- Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. (2014) pubmed
- Cystic Fibrosis: A Review. (2023) pubmed
- Ivacaftor for the treatment of cystic fibrosis in children under six years of age. (2020) pubmed
- Tezacaftor and ivacaftor for the treatment of cystic fibrosis. (2020) pubmed